TCM
DFTX

TruNorth Capital Management’s Definium Therapeutics DFTX Stock Holding History

TruNorth Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33
Closed -$214 – 415
2025
Q2 		$214 Hold
33
– – ﹤0.01% 349
2025
Q1 		$193 Hold
33
– – ﹤0.01% 429
2024
Q4 		$230 Hold
33
– – ﹤0.01% 367
2024
Q3 		$188 Hold
33
– – ﹤0.01% 391
2024
Q2 		$238 Buy
+33
New +$289 ﹤0.01% 348

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TruNorth Capital Management's DFTX Position: Q3 2025 in Review

TruNorth Capital Management sold out of Definium Therapeutics (DFTX) in Q3 2025, closing a stake of 33 shares — an estimated $214 sold.

TruNorth Capital Management first reported a position in DFTX in Q2 2024 and held it in 5 quarters. The position peaked at $238 in Q2 2024. 195 funds tracked by Wall St. Rank hold DFTX as of Q3 2025.

  • TruNorth Capital Management reported no remaining Definium Therapeutics position as of Q3 2025 after selling out during the quarter.
  • TruNorth Capital Management sold 33 Definium Therapeutics shares in Q3 2025, an estimated $214.
  • TruNorth Capital Management first reported a position in Definium Therapeutics in Q2 2024 and held it in 5 quarters.
  • TruNorth Capital Management's Definium Therapeutics position peaked at $238 in Q2 2024.
  • 195 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2025.

Based on TruNorth Capital Management's 13F filing for Q3 2025, filed 21 Oct 2025.